Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Applied Genetic Technologies Corp (NASDAQ: AGTC).

Full DD Report for AGTC

You must become a subscriber to view this report.


Recent News from (NASDAQ: AGTC)

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q3 2018 Results - Earnings Call Transcript
Applied Genetic Technologies Corporation (AGTC) Q3 2018 Earnings Conference Call May 08, 2018 04:30 PM ET Executives Sue Washer - Chief Executive Officer Bill Sullivan - Chief Financial Officer Matt Feinsod - Chief Medical Officer Analysts Yanan Zhu - Wells Fargo Pete Sta...
Source: SeekingAlpha
Date: May, 11 2018 22:07
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced ...
Source: GlobeNewswire
Date: May, 08 2018 16:05
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 8, 2018
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...
Source: GlobeNewswire
Date: April, 30 2018 07:00
AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...
Source: GlobeNewswire
Date: April, 18 2018 07:00
AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announce...
Source: GlobeNewswire
Date: April, 10 2018 09:30
"Cheap Investor" Sees Value at Applied Genetic Technologies
Applied Genetic Technologies ( AGTC ) is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases, explains Bill Mathews , editor of The Cheap Investor ...
Source: MoneyShow.com
Date: March, 13 2018 01:00
AGTC Announces Sue Washer, CEO, Elected to Biotechnology Innovation Organization's Board of Directors
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announce...
Source: GlobeNewswire
Date: February, 14 2018 16:05
Wired News - Catalyst Biosciences Shares Positive Top-line Data from Phase-1/2 Study of Subcutaneous CB 2679d for Hemophilia B
Stock Monitor: Applied Genetic Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Catalyst Biosciences, Inc. (NASDAQ: CBIO ). If you want access to this report all you need to do is sign ...
Source: ACCESSWIRE IA
Date: February, 12 2018 07:50
Finding Biotech Value In All-Time Highs
Altum Research is about finding value. While I am definitely not complaining that biotech has rallied, some very interesting companies ([[SAGE]], [[FATE]], [[PIRS]], [[CBAY]], [[SGMO]], etc.) are just too high in price for me to put money in. However there is always value in biotech, sometimes...
Source: SeekingAlpha
Date: February, 10 2018 00:56
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2018 Results - Earnings Call Transcript
Applied Genetic Technologies Corporation (AGTC) Q2 2018 Earnings Conference Call February 9, 2018 08:00 ET Executives Sue Washer - President and Chief Executive Officer Bill Sullivan - Chief Financial Officer Matt Feinsod - Chief Medical Officer Analysts Matthew Luchini - B...
Source: SeekingAlpha
Date: February, 09 2018 09:57

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-185.605.505.6055.4070,862
2018-05-175.605.505.6055.4070,862
2017-06-205.255.255.35185.10223,526
2017-06-195.055.205.255.05315,278
2017-06-165.105.055.154.90361,540

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2492,885128,37672.3539Short
2018-05-236,60913,21050.0303Short
2018-05-2215,62029,78052.4513Short
2018-05-2114,21031,17745.5785Short
2018-05-189,08519,93945.5640Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AGTC.


About Applied Genetic Technologies Corp (NASDAQ: AGTC)

Logo for Applied Genetic Technologies Corp (NASDAQ: AGTC)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AGTC)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 06 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 06 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 02 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: February, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: January, 29 2018

       

       


      Daily Technical Chart for (NASDAQ: AGTC)

      Daily Technical Chart for (NASDAQ: AGTC)


      Stay tuned for daily updates and more on (NASDAQ: AGTC)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AGTC)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      Monsta Trader
      @MonstaTrader

       

       


      Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AGTC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of AGTC and does not buy, sell, or trade any shares of AGTC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/